This Article Abstract Full Text Full Text (PDF) View Online Appendix Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (41) Citing Articles via Google Scholar Google Scholar Articles by Richards, M. Search for Related Content PubMed PubMed Citation Articles by Richards, M.

Comparison of B-Type Natriuretic Peptides for Assessment of Cardiac Function and Prognosis in Stable Ischemic Heart Disease

Mark Richards, MD^_*,_*, M. Gary Nicholls, MD^_*, Eric A. Espiner, MD^_*, John G. Lainchbury, MD^_*, Richard W. Troughton, MD^_*, John Elliott, MD^_*, Christopher M. Frampton, PhD^_*, Ian G. Crozier, MD^_*, Timothy G. Yandle, PhD^_*, Robert Doughty, MD^,, Stephen MacMahon, PhD^,, Norman Sharpe, MD^, for the Christchurch Cardioendocrine Research Group and the Australia-New Zealand Heart Failure Group

^_* Christchurch Cardioendocrine Research Group, Christchurch Hospital, Christchurch, New Zealand
Australia-New Zealand Heart Failure Group
Department of Medicine, University of Auckland, Auckland, New Zealand
Institute for International Health, Newtown, Sydney, New South Wales, Australia

View larger version (33K): [in a new window]   Figure 1 Plasma brain natriuretic peptide (BNP) plotted against plasma amino terminal pro-brain natriuretic peptide (NTproBNP) in 1,049 patients with stable ischemic heart disease.

View larger version (50K): [in a new window]   Figure 2 Left ventricular ejection fraction (LVEF) plotted against brain natriuretic peptide (BNP) (closed symbols) and amino terminal pro-brain natriuretic peptide (NTproBNP) (open symbols) in 1,049 patients with stable ischemic heart disease.

View larger version (51K): [in a new window]   Figure 3 Age (top) and creatinine clearance (CrCl) (bottom) plotted against brain natriuretic peptide (BNP) (closed symbols) and amino terminal pro-brain natriuretic peptide (NTproBNP) (open symbols) in 1,049 patients with stable ischemic heart disease.

View larger version (38K): [in a new window]   Figure 4 Body mass index plotted against brain natriuretic peptide (BNP) (closed symbols) and amino terminal pro-brain natriuretic peptide (NTproBNP) (open symbols) in 1,049 patients with stable ischemic heart disease.

View larger version (17K): [in a new window]   Figure 5 Receiver-operating characteristic curves for detection of left ventricular ejection fraction (LVEF) <30% (top), 40% (middle), or 50% (bottom) by brain natriuretic peptide (BNP) (solid lines) and amino terminal pro-brain natriuretic peptide (NTproBNP) (dotted lines) in 1,049 patients with stable ischemic heart disease. Curves do not significantly differ for any level of LVEF. AUC = area under the curve.

View larger version (16K): [in a new window]   Figure 6 Receiver-operating characteristic curves for detection of left ventricular ejection fraction (LVEF) <30% (top), 40% (middle), and 50% (bottom) by brain natriuretic peptide (BNP) (solid lines) or amino terminal pro-brain natriuretic peptide (NTproBNP) (dotted lines) in 1,049 patients with asymptomatic stable ischemic heart disease. AUC = area under the curve.

View larger version (20K): [in a new window]   Figure 7 Kaplan-Meier event-free survival curves for death or heart failure admission for those with brain natriuretic peptide (BNP) (solid lines) and amino terminal pro-brain natriuretic peptide (NTproBNP) (dotted lines) above (lower two lines) or below (upper two lines) the median level for the group. For both peptides, the separation of survival curves was highly significant (p < 0.001). CHF = congestive heart failure.